<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489838</url>
  </required_header>
  <id_info>
    <org_study_id>ULAB11069</org_study_id>
    <nct_id>NCT02489838</nct_id>
  </id_info>
  <brief_title>Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma</brief_title>
  <official_title>Analysis of Lung Dose Using Volumetric Analysis in Patients Treated With Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alan Katz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for&#xD;
      Liver Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of&#xD;
      patients with unresectable hepatocellular carcinoma who undergo selective internal radiation&#xD;
      therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to&#xD;
      the lung dose estimated by established criteria. In addition, this study, will summarize the&#xD;
      pre and post-treatment clinical data to describe the URMC Y-90 experience.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2012</start_date>
  <completion_date type="Actual">August 7, 2019</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung dose measured with actual lung mass vs Lung dose measured with conventional method.</measure>
    <time_frame>1 month after treatment.</time_frame>
    <description>Lung dose measured with actual lung mass vs Lung dose measured with conventional method which assumes 1 kg for all patients.&#xD;
Patient will be receiving this treatment even if not enrolled on this study.&#xD;
The study is NOT about the intervention given to the patient. The study is to determine the best way to measure the radiation dose normal tissue (the lung specifically) receives during this standard treatment.</description>
  </primary_outcome>
  <enrollment type="Actual">56</enrollment>
  <condition>Liver Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer Patients at the University of Rochester&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed&#xD;
             therapy&#xD;
&#xD;
          -  Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or&#xD;
             other metastatic diseases to be treated with SIRT (Y-90)&#xD;
&#xD;
          -  surgical resection not feasible at time of initiation of pre-treatment workup&#xD;
&#xD;
             -&gt; 6 months projected life span&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous radioembolization of one or more liver lobes or segments without available&#xD;
             treatment planning and procedural documentation ie. at another facility prior to URMC&#xD;
             Y-90 radioembolization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universtiy of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation Oncology, University of Rochester, Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Alan Katz</investigator_full_name>
    <investigator_title>Associate Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Liver Neoplasma</keyword>
  <keyword>Lung Radiation dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

